- Home
- TNGX vs LOCO Comparison
TNGX vs LOCO Comparison
Compare TNGX & LOCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNGX | LOCO |
|---|---|---|
| Founded | 2014 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 399.0M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TNGX | LOCO |
|---|---|---|
| Price | $21.57 | $13.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $20.00 | $13.50 |
| AVG Volume (30 Days) | ★ 3.7M | 429.1K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.89 | 4.65 |
| EPS | N/A | ★ 0.90 |
| Revenue | $62,384,000.00 | ★ $401,701,000.00 |
| Revenue This Year | N/A | $3.46 |
| Revenue Next Year | N/A | $4.11 |
| P/E Ratio | ★ N/A | $15.43 |
| Revenue Growth | ★ 48.29 | 5.68 |
| 52 Week Low | $1.04 | $8.29 |
| 52 Week High | $22.20 | $14.50 |
Technical Indicators
Market Signals| Indicator | TNGX | LOCO |
|---|---|---|
| Relative Strength Index (RSI) | 74.32 | 69.77 |
| Support Level | $5.98 | $10.21 |
| Resistance Level | $21.82 | $14.50 |
| Average True Range (ATR) | 1.24 | 0.53 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 90.10 | 68.39 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.